#BEGIN_DRUGCARD DB03434

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
44115

# Chemical_Formula:
C7H15NO4S

# Chemical_IUPAC_Name:
3-(morpholin-4-yl)propane-1-sulfonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
3[N-Morpholino]Propane Sulfonic Acid

# HET_ID:
MPO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C7H15NO4S/c9-13(10,11)7-1-2-8-3-5-12-6-4-8/h1-7H2,(H,9,10,11)

# InChI_Key:
InChIKey=DVLFYONBTKHTER-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3434

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
209.263

# Molecular_Weight_Mono:
209.072178663

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EYZ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.6

# Predicted_LogS:
-0.75

# Predicted_Water_Solubility:
3.72e+01 g/l

# Primary_Accession_No:
DB03434

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
70807

# PubChem_Substance_ID:
46506417

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02224

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OS(=O)(=O)CCCN1CCOCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:15 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L10328

# Drug_Target_1_GenBank_ID_Protein:
290506

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
yicI

# Drug_Target_1_Gene_Sequence:
>2319 bp
TTACAACGTAATTGTCAGCGCATTCCCTTGAGGCTTCACCACCAGCCCCTGCTCACTTTC
AGCCTGCGAACCGTCTTGCAGACCATTTACTTTCACAACATTGCGCAGGCACAGTGTCCA
GTTCTTCGCCTCGCCCGCACCAGTCACAGTAATCGTGTTGCCAGTACGTGCTGCTTTTAA
AGTAAAGATCACCGATCCGTCAGCAGCGGGCACTTCACAGACGGCTTCATGCCCGTCTTG
CAGATTGAAGAGGTGGAATGCCGTGCCTTCGTGCCACACGTAATCGGGACGTTGATCGTT
GTTGCCCAGCGCCAGTAGAGTGTTATCACGCACATAAACGGGCAGACTCAGGAAGCCGTG
CTGCTGTTTATGCCAGCGACTACCGTCGAGTTCATCGTTGTGCCACAGGTGTGTCCAGCG
ACCTTCCGGCAGGTAGAACTGCACATCGCCCGCTTCAGTGAACACCGGCGCAACCATCAC
GTTGTCGCCTAACATGTATTGACGGTCAAGGTAATCACAAGCCGGATCGTCCGGGAACTC
CATCATCATGGCCCGCATCATCGGCGTACCCCGCGCGTTCGCACGCGNAGCTTCACGATA
CAGATACGGCATCATGCGGCATTTCAGTTGCGTGAAGAAGCGCACCACATCACAGGACTC
ATCATCGTAGGCCCACGNNACACGATAAGATTTGCTACCGTGTAAACGGCTATGGCTGGA
GAGCAAACCAAACGCGCACCAGCGTTTGTAAACGTGCGCCGGAGCGGTATTTTCAAAGCC
GCCGATATCGTGGCTCCAGAAGCCAAAACCTGAAAGGCCAATAGACAAACCACCGCGCAG
GCTTTCCGCCATTGATTCGTAGTTAGCGTAACAATCGCCACCCCAGTGTACCGGGAATTT
CTGCGCACCGACGGAGGCCGAGCGGGCAAACAAGACAGCTTCTTCCTCACCAACGGTGTC
CTTGAGCACGTTCCACACCAGTTCGTTGTAGATGTACGCATAATGGTTATGCATTTTCTG
CGGATCGGAACCGTCAAACCACTGAACATCAGTTGGGATACGTTCGCCAAAGTCGGTCTT
AAAGCAATCAACGCCCATCGCGACCAGACCTTTCAGTTTGTCGGCGTACCATTTGCAGGC
ATCCGGATTGGTAAAGTCATAAATCGCCAGACCTGGCTGCCATTTATCCCACTGCCATAG
CGAACCGTCCGGGCGTTTGAGTAAATAGCCTTTCTCTTGTAACTCTTTAAAGACGGGGGA
TTTTTGACCGATATAGGGGTTAATCCAGACGCAGATTTTCAGTCCTTTCGCTTTCAGGCG
GCGGATCATCCCTTCCGGGTCAGGGAAAGTCAGCGGGTCCCACTCAAAATCGCACCACTG
GAAGGCTTTCATCCAGAAACAGTCAAAGTGGAAAACATGCAGCGGCAGATTGCGTTCCGC
CATACCATCGATAAAGCTGTTTACCGTCGCTTCGTCGTAGTTGGTGGTAAATGAAGTGGT
TANNCACAGGCCGAAGGACCACGCGGGCGNCANNGCCGGACGACCAGTAAAGCGGGTATA
ACGATCAAGTACCGCTTTCGGCGTCGGGCCGTCGATAACAAAGTATTCGAGATATTCACT
CTCAACGCTGAACTGCACTTTGGAGACTTTCTCCGATCCCACTTCAAAAGAGACACACTG
GGGATGATTGACCAGTACCCCATAACCACGGTTAGTCATGTAGAACGGGATATTTTTATA
CGCCTGTTCAGTACTTGTGCCGCCGTCCCGGTTCCAGGTCTCTACCGTCTGGCCATTGCG
CACCAGGGCAGTAAAGCGCTCTCCCAGACCGTAAACTGTTTCGCCAACGCCAAGATCAAG
CCGCTCAAACATATAATTGCGTTGATTATTCGTGTCCTGCACGTAGCCATTATTTTTCAC
CTGACTACCGGTAATACGTTCGCCGTTGCGCAGAAAATCCAGTGACCAGAACTCACCTTT
GCTGACACGCGCGCTTAAGTTGCCACTTTTAAACTCAGCATAACGTTCTGTGTTTTCGAT
TGTGACCTTCACGTCCTGCAAAATATTGAGCGGATAATGAGGACCGTTATTCAGCGCCCC
CTGAAAATGCTCAATCCGCACACCGACAATACCTTCCTGTGGGGAGAAAAAGCGCAACGT
AAATAAAGGCGTATCAAGCTGCCAGGTACGTTCACGCACATCACGGGGGGCAGCATAGAC
CACCATTTCATTATCCTGCTGTTCAACCTCGAACACCTGAAGCGGGTGAATCAAATTGAG
GCCAGGTTGAATCAACCAGTTTCCATCGCTAATTTTCAT

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3500

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
88080

# Drug_Target_1_Name:
Putative family 31 glucosidase yicI

# Drug_Target_1_Number_of_Residues:
772

# Drug_Target_1_PDB_ID:
1XSK

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01055	Glyco_hydro_31

# Drug_Target_1_Protein_Sequence:
>Putative family 31 glucosidase yicI
MKISDGNWLIQPGLNLIHPLQVFEVEQQDNEMVVYAAPRDVRERTWQLDTPLFTLRFFSP
QEGIVGVRIEHFQGALNNGPHYPLNILQDVKVTIENTERYAEFKSGNLSARVSKGEFWSL
DFLRNGERITGSQVKNNGYVQDTNNQRNYMFERLDLGVGETVYGLGERFTALVRNGQTVE
TWNRDGGTSTEQAYKNIPFYMTNRGYGVLVNHPQCVSFEVGSEKVSKVQFSVESEYLEYF
VIDGPTPKAVLDRYTRFTGRPALPPAWSFGLWLTTSFTTNYDEATVNSFIDGMAERNLPL
HVFHFDCFWMKAFQWCDFEWDPLTFPDPEGMIRRLKAKGLKICVWINPYIGQKSPVFKEL
QEKGYLLKRPDGSLWQWDKWQPGLAIYDFTNPDACKWYADKLKGLVAMGVDCFKTDFGER
IPTDVQWFDGSDPQKMHNHYAYIYNELVWNVLKDTVGEEEAVLFARSASVGAQKFPVHWG
GDCYANYESMAESLRGGLSIGLSGFGFWSHDIGGFENTAPAHVYKRWCAFGLLSSHSRLH
GSKSYRVPWAYDDESCDVVRFFTQLKCRMMPYLYREAARANARGTPMMRAMMMEFPDDPA
CDYLDRQYMLGDNVMVAPVFTEAGDVQFYLPEGRWTHLWHNDELDGSRWHKQQHGFLSLP
VYVRDNTLLALGNNDQRPDYVWHEGTAFHLFNLQDGHEAVCEVPAADGSVIFTLKAARTG
NTITVTGAGEAKNWTLCLRNVVKVNGLQDGSQAESEQGLVVKPQGNALTITL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P31434

# Drug_Target_1_SwissProt_Name:
XYLS_ECOLI

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
5.61

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein. Note=Located in the cytotoxic granules of T-cells, which are released upon antigen

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GNLY

# Drug_Target_2_GenBank_ID_Gene:
X05044

# Drug_Target_2_GenBank_ID_Protein:
36668

# Drug_Target_2_GeneCard_ID:
GNLY

# Drug_Target_2_Gene_Name:
GNLY

# Drug_Target_2_Gene_Sequence:
>390 bp
ATGGAAGGTCTGGTCTTCTCTCGTCTGAGCCCTGAGTACTACGACCCGGCAAGAGCCCAC
CTGCGTGATGGGGAGAAATCCTGCCCGTGCGGGCAGGAGGGCCCCCAGGGTGACCTGTTG
ACCAAAACACAGGAGCTGGGCCGTGACTACAGGACCTGTCTGACGATAGTCCAAAAACTG
AAGAAGATGGTGGATAAGCCCACCCAGAGAAGTGTTTCCAATGCTGCGACCCGGGTGTGT
AGGACGGGGAGGTCACGATGGCGCGACGTCTGCAGAAATTTCATGAGGAGGTATCAGTCT
AGAGTTATCCAAGGCCTCGTGGCCGGAGAAACTGCCCAGCAGATCTGTGAGGACCTCAGG
TTGTGTATACCTTCTACAGGTCCCCTCTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
10449094	Hanson DA, Kaspar AA, Poulain FR, Krensky AM: Biosynthesis of granulysin, a novel cytolytic molecule. Mol Immunol. 1999 May;36(7):413-22.
10644038	Krensky AM: Granulysin: a novel antimicrobial peptide of cytolytic T lymphocytes and natural killer cells. Biochem Pharmacol. 2000 Feb 15;59(4):317-20.
2212946	Yabe T, McSherry C, Bach FH, Houchins JP: A cDNA clone expressed in natural killer and T cells that likely encodes a secreted protein. J Exp Med. 1990 Oct 1;172(4):1159-63.
2434598	Jongstra J, Schall TJ, Dyer BJ, Clayberger C, Jorgensen J, Davis MM, Krensky AM: The isolation and sequence of a novel gene from a human functional T cell line. J Exp Med. 1987 Mar 1;165(3):601-14.
8423048	Houchins JP, Kricek F, Chujor CS, Heise CP, Yabe T, McSherry C, Bach FH: Genomic structure of NKG5, a human NK and T cell-specific activation gene. Immunogenetics. 1993;37(2):102-7.
9756476	Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Uszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL: An antimicrobial activity of cytolytic T cells mediated by granulysin. Science. 1998 Oct 2;282(5386):121-5.

# Drug_Target_2_HGNC_ID:
HGNC:4414

# Drug_Target_2_HPRD_ID:
01788

# Drug_Target_2_ID:
3514

# Drug_Target_2_Locus:
2p12-q11

# Drug_Target_2_Molecular_Weight:
16374

# Drug_Target_2_Name:
Granulysin

# Drug_Target_2_Number_of_Residues:
145

# Drug_Target_2_PDB_ID:
1L9L

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF03489	SapB_2

# Drug_Target_2_Protein_Sequence:
>Granulysin precursor
MATWALLLLAAMLLGNPGLVFSRLSPEYYDLARAHLRDEEKSCPCLAQEGPQGDLLTKTQ
ELGRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQ
GLVAGETAQQICEDLRLCIPSTGPL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-22

# Drug_Target_2_Specific_Function:
Antimicrobial protein that kills intracellular pathogens. Active against a broad range of microbes, including Gram-positive and Gram-negative bacteria, fungi, and parasites. Kills Mycobacterium tuberculosis

# Drug_Target_2_SwissProt_ID:
P22749

# Drug_Target_2_SwissProt_Name:
GNLY_HUMAN

# Drug_Target_2_Synonyms:
Granulysin precursor
Lymphokine LAG-2
Protein NKG5
T-cell activation protein 519

# Drug_Target_2_Theoretical_pI:
9.40

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L20897

# Drug_Target_3_GenBank_ID_Protein:
304887

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
purT

# Drug_Target_3_Gene_Sequence:
>1179 bp
ATGACGTTATTAGGCACTGCGCTGCGTCCGGCAGCAACTCGCGTGATGTTATTAGGCTCC
GGTGAACTGGGTAAAGAAGTGGCAATCGAGTGTCAGCGTCTCGGCGTAGAGGTGATTGCC
GTCGATCGCTATGCCGACGCACCAGCCATGCATGTCGCGCATCGCTCCCATGTCATTAAT
ATGCTTGATGGTGATGCATTACGCCGTGTGGTTGAACTGGAAAAACCACATTATATCGTG
CCGGAGATCGAAGCTATTGCCACCGATATGCTGATCCAACTTGAAGAGGAAGGACTGAAT
GTTGTCCCCTGCGCTCGCGCAACGAAATTAACGATGAATCGCGAGGGTATCCGTCGCCTG
GCGGCAGAAGAGCTGCAGCTGCCCACTTCCACTTATCGTTTTGCCGATAGCGAAAGCCTT
TTCCGCGAGGCGGTTGCTGACATTGGCTATCCCTGCATTGTAAAACCGGTGATGAGCTCT
TCCGGCAAGGGGCAGACGTTTATTCGTTCTGCAGAGCAACTTGCTCAGGCATGGAAGTAC
GCTCAGCAAGGCGGTCGCGCCGGAGCGGGCCGCGTAATTGTTGAAGGCGTCGTTAAGTTT
GACTTCGAAATTACCCTGCTAACCGTCAGCGCGGTGGATGGCGTCCATTTCTGTGCACCA
GTAGGTCATCGCCAGGAAGATGGCGACTACCGTGAATCCTGGCAACCACAGCAAATGAGC
CCGCTTGCCCTTGAACGTGCGCAGGAGATTGCCCGTAAAGTGGTGCTGGCACTGGGCGGT
TATGGGTTGTTTGGTGTCGAGCTATTTGTCTGTGGTGATGAGGTGATTTTCAGTGAGGTC
TCCCCTCGTCCACATGATACCGGGATGGTGACGTTAATTTCTCAAGATCTCTCAGAGTTT
GCCCTGCATGTACGTGCCTTCCTCGGACTTCCGGTTGGCGGGATCCGTCAGTATGGTCCT
GCAGCTTCTGCCGTTATTCTGCCACAACTGACCAGTCAGAATGTCACGTTTGATAATGTG
CAGAATGCCGTAGGCGCAGATTTGCAGATTCGTTTATTTGGTAAGCCGGAAATTGATGGC
AGCCGTCGTCTGGGGGTGGCACTGGCTACTGCAGAGAGTGTTGTTGACGCCATTGAACGC
GCGAAGCACGCCGCCGGACAGGTAAAAGTACAGGGTTAA

# Drug_Target_3_General_Function:
Nucleotide transport and metabolism

# Drug_Target_3_General_References:
10913290	Thoden JB, Firestine S, Nixon A, Benkovic SJ, Holden HM: Molecular structure of Escherichia coli PurT-encoded glycinamide ribonucleotide transformylase. Biochemistry. 2000 Aug 1;39(30):8791-802.
8117714	Marolewski A, Smith JM, Benkovic SJ: Cloning and characterization of a new purine biosynthetic enzyme: a non-folate glycinamide ribonucleotide transformylase from E. coli. Biochemistry. 1994 Mar 8;33(9):2531-7.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2817

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
42434

# Drug_Target_3_Name:
Phosphoribosylglycinamide formyltransferase 2

# Drug_Target_3_Number_of_Residues:
392

# Drug_Target_3_PDB_ID:
1EZ1

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02222	ATP-grasp

# Drug_Target_3_Protein_Sequence:
>Phosphoribosylglycinamide formyltransferase 2
MTLLGTALRPAATRVMLLGSGELGKEVAIECQRLGVEVIAVDRYADAPAMHVAHRSHVIN
MLDGDALRRVVELEKPHYIVPEIEAIATDMLIQLEEEGLNVVPCARATKLTMNREGIRRL
AAEELQLPTSTYRFADSESLFREAVADIGYPCIVKPVMSSSGKGQTFIRSAEQLAQAWKY
AQQGGRAGAGRVIVEGVVKFDFEITLLTVSAVDGVHFCAPVGHRQEDGDYRESWQPQQMS
PLALERAQEIARKVVLALGGYGLFGVELFVCGDEVIFSEVSPRPHDTGMVTLISQDLSEF
ALHVRAFLGLPVGGIRQYGPAASAVILPQLTSQNVTFDNVQNAVGADLQIRLFGKPEIDG
SRRLGVALATAESVVDAIERAKHAAGQVKVQG

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes two reactions:the first one is the production of beta-formyl glycinamide ribonucleotide (GAR) from formate, ATP and beta GAR; the second, a side reaction, is the production of acetyl phosphate and ADP from acetate and ATP

# Drug_Target_3_SwissProt_ID:
P33221

# Drug_Target_3_SwissProt_Name:
PURT_ECOLI

# Drug_Target_3_Synonyms:
5'-phosphoribosylglycinamide transformylase 2
EC 2.1.2.-
Formate-dependent GAR transformylase
GAR transformylase 2
GART 2

# Drug_Target_3_Theoretical_pI:
5.46

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB03434
